• FDA cleared Novartis’ Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines.
• Decision makes Rhapsido the first approved treatment for the condition, adding to its earlier U.S. use in chronic spontaneous urticaria.
• Phase III RemIND data showed complete hive resolution at Week 12 in 29.3% on Rhapsido vs 14.0% on placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610071145OMX_____CNEWS_EN_GNW1001276801_en) on October 07, 2026, and is solely responsible for the information contained therein.